Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fingolimod
Drug ID BADD_D02464
Description Multiple sclerosis or MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects.[A176474] Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010.[L12651] Fingolimod is currently being studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus. Phase 2 clinical trials are currently underway and completion is expected in July 2020.[L12654]
Indications and Usage Fingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
Marketing Status Not Available
ATC Code L04AA27
DrugBank ID DB08868
KEGG ID D10001
MeSH ID D000068876
PubChem ID 107970
TTD Drug ID D07UHS
NDC Product Code 54893-0026; 65035-201
Synonyms Fingolimod Hydrochloride | 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride | FTY-720 | FTY 720 | FTY720 | Gilenya | Gilenia | Fingolimod
Chemical Information
Molecular Formula C19H33NO2
CAS Registry Number 162359-55-9
SMILES CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Alanine aminotransferase decreased13.03.01.0020.009843%Not Available
Alanine aminotransferase increased13.03.01.0030.303971%
Alopecia23.02.02.0010.117535%
Altered state of consciousness19.07.01.003; 17.02.04.001--Not Available
Amaurosis fugax17.08.04.002; 24.04.06.006; 06.02.02.0050.001158%Not Available
Amenorrhoea05.05.01.002; 21.01.02.0010.012159%
Amnesia19.20.01.001; 17.03.02.0010.052109%
Amylase increased13.05.01.009--
Anaemia01.03.02.001--
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Anaplastic astrocytoma17.20.02.004; 16.30.02.0040.000453%Not Available
Aneurysm24.02.01.0010.001359%Not Available
Anger19.04.02.001--Not Available
Angina pectoris24.04.04.002; 02.02.02.0020.033582%
Angina unstable02.02.02.004; 24.04.04.004--Not Available
Angioedema23.04.01.001; 10.01.05.009--Not Available
Angle closure glaucoma06.03.01.001--Not Available
Angular cheilitis23.03.03.054; 11.01.04.014; 07.05.07.0130.001158%Not Available
Anisocytosis01.07.02.0080.001158%Not Available
Ankle fracture15.08.03.005; 12.04.01.0050.015054%
Ankylosing spondylitis10.04.04.004; 15.01.09.0010.002316%Not Available
Anxiety19.06.02.0020.140695%
Aortic aneurysm24.02.03.0010.001737%Not Available
Aortic dissection24.02.03.002--Not Available
Apathy19.04.04.0020.006948%Not Available
Aphasia19.21.01.001; 17.02.03.0010.044003%
Aphonia19.19.01.002; 22.02.05.024; 17.02.08.0090.003474%
Aphthous ulcer07.05.06.0020.011001%Not Available
Aplasia08.03.04.003; 03.02.01.0020.001158%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 63 Pages